What is so amusing about Bloomberg’s science page reporting that doctors should consider other medicines, such as GlaxoSmithKline Plc's Relenza, to fight a disease the WHO estimates causes 250,000 to 500,000 deaths annually.
Even if comments re BTA management and staff have basis, this is now in the hands of GSK.
Surely BTA have future developmental projects in mind if greater royalties are received.
I can understand the negativity considering past performance but I consider the future (perhaps only short term) to be positive.
Recent investor and happy to be one. And that’s right… it is my money!
BTA Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
